12:18:25 EDT Tue 16 Jul 2019
Enter Symbol
or Name

Login ID:
Aptose Biosciences Inc (2)
Symbol C : APS
Shares Issued 39,215,348
Close 2019-03-01 C$ 2.36
Recent Sedar Documents

Aptose receives Australian patent for CG-806

2019-03-04 08:22 ET - News Release

Mr. Greg Chow reports


The Australian Patent Office (APO) has issued Australian patent No. 2013371146 for Aptose Biosciences Inc.'s CG-806, a first-in-class, highly potent oral small molecule being developed for acute myeloid leukemia (AML), B cell and other hematologic malignancies. The granted patent claims various compounds, including the CG-806 compound, pharmaceutical compositions comprising the CG-806 compound, and uses for the treatment of various diseases, such as lymphoma or leukemia. The patent is expected to provide protection until December of 2033.

About CG-806

CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multicluster kinase inhibitor. This small molecule, in licensed from CrystalGenomics Inc. in Seoul, South Korea, demonstrates potent inhibition of wild type and all mutant forms of FLT3 (including internal tandem duplication, or ITD, and mutations of the receptor tyrosine kinase domain and gatekeeper region), cures animals of acute myeloid leukemia (AML) tumours in the absence of toxicity in murine xenograft models, and represents a potential best-in-class therapeutic for patients with AML. Likewise, CG-806 demonstrates potent, non-covalent inhibition of the wild type and Cys481Ser (C481S) mutant forms of the BTK enzyme, as well as other oncogenic kinase pathways operative in B cell malignancies, suggesting CG-806 may be developed for various B cell malignancy patients (including CLL, MCL, DLBCL and others) that are resistant/refractory/intolerant to covalent BTK inhibitors. Because CG-806 targets key kinases/pathways operative in malignancies derived from the bone marrow, it is in development for B cell cancers and AML.

About Aptose Biosciences Inc.

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.